ubrelvy
Pharmaranks rates Ubrelvy 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Ubrelvy (Ubrogepant) is a calcitonin gene-related peptide receptor antagonist used to treat Migraine Disorders, Migraine with Aura, Migraine Without Aura.
Ubrogepant · by Abbvie
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Ubrogepant
- Form
- Tablet
- Strength
- Ubrogepant 100MG · Ubrogepant 50MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Abbvie
- FDA application
- NDA211765
Drug class
May treat (source: NIH RxClass)
See how Ubrelvy ranks — best-rated calcitonin gene-related peptide receptor antagonist for:
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Ubrelvy treat?
- Ubrelvy (Ubrogepant) may be used to treat migraine disorders, migraine with aura, migraine without aura, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Ubrelvy rated?
- pharmaranks gives Ubrelvy a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Ubrelvy?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Ubrelvy. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Ubrelvy?
- Ubrelvy is marketed by Abbvie. You can see Abbvie's full profile, rating, and other products on pharmaranks.
- Is Ubrelvy a brand-name or generic drug?
- Ubrelvy is a brand-name product with the active ingredient Ubrogepant.
- Is Ubrelvy available over the counter?
- No. Ubrelvy is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Ubrelvy come in?
- Ubrelvy is currently marketed as tablet, per the FDA's National Drug Code Directory.
- What class of drug is Ubrelvy?
- Ubrelvy is classified as calcitonin gene-related peptide receptor antagonist, per the FDA's Established Pharmacologic Class.
- Is Ubrelvy FDA-registered?
- Ubrelvy is on record with the U.S. FDA under application number NDA211765. You can verify this on its official FDA label.
- Has Ubrelvy been recalled by the FDA?
- Ubrelvy has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Ubrelvy safe?
- There's no single safe-or-not verdict. pharmaranks gives Ubrelvy a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about UBROGEPANT
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 250 reports naming UBROGEPANT — the active ingredient in Ubrelvy, and the FDA flagged 57% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- migraine36 reports
- nausea27 reports
- headache22 reports
- fatigue14 reports
- dizziness13 reports
- arthralgia10 reports
- diarrhoea10 reports
- injection site pain10 reports
Read these as a signal, not a rate. A report does not mean UBROGEPANT caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Ubrelvy head-to-head
Guides for this medication
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
ubrelvy
72/100